Butler J, Attiyeh F F, Daly J M
Surg Gynecol Obstet. 1986 Feb;162(2):109-13.
Hepatic resection is the treatment of choice for a solitary metastatic deposit from a primary carcinoma of the large intestine in the absence of extrahepatic disease. This study was done to evaluate hepatic resection in the treatment of multiple hepatic metastases from carcinoma of the colon and rectum. Sixty-two patients underwent hepatic resection with an over-all operative mortality of 10 per cent, but a recent (1968-1981) mortality of 2 per cent. Three, five and ten year survival rates were 50, 34 and 21 per cent, respectively. No significant differences in survival patterns were noted comparing site (colon versus rectum), time interval from diagnosis of the primary to diagnosis of metastases (synchronous versus metachronous), sex (male versus female), size of the metastatic lesion (less than 5 centimeters versus greater than or equal to 5 centimeters) or number of metastatic lesions (single versus multiple). The pathologic stage of the primary carcinoma of the large intestine significantly (p less than 0.05) influenced survival patterns after hepatic resection with Dukes' B primary tumor having a median survival time of 123 months versus 27 months for patients with Dukes' C primary tumor. Sixty-seven per cent of those with a recurrence did so within the liver. Adjuvant chemotherapy had no demonstrable effect on survival patterns. Further improvement in survival statistics will require more sensitive staging procedures and effective adjuvant therapy, particularly for patients with Dukes' C primary carcinoma of the large intestine.
对于无肝外病变的大肠原发性癌孤立性肝转移灶,肝切除术是首选的治疗方法。本研究旨在评估肝切除术在治疗结肠和直肠癌多发肝转移中的作用。62例患者接受了肝切除术,总体手术死亡率为10%,但近期(1968 - 1981年)死亡率为2%。3年、5年和10年生存率分别为50%、34%和21%。比较部位(结肠与直肠)、从原发性癌诊断到转移灶诊断的时间间隔(同时性与异时性)、性别(男性与女性)、转移灶大小(小于5厘米与大于或等于5厘米)或转移灶数量(单个与多个),在生存模式上未发现显著差异。大肠原发性癌的病理分期对肝切除术后的生存模式有显著影响(p < 0.05),Dukes' B期原发性肿瘤患者的中位生存时间为123个月,而Dukes' C期原发性肿瘤患者为27个月。67%的复发患者复发部位在肝脏。辅助化疗对生存模式没有明显影响。生存统计的进一步改善将需要更敏感的分期程序和有效的辅助治疗,特别是对于大肠Dukes' C期原发性癌患者。